[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Nanocarrier-Based Vaccine Market Insights, Forecast to 2029

December 2023 | 92 pages | ID: GB8D90117AB6EN
QYResearch

US$ 4,900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report presents an overview of global market for Nanocarrier-Based Vaccine market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Nanocarrier-Based Vaccine, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Nanocarrier-Based Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nanocarrier-Based Vaccine revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Nanocarrier-Based Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Nanocarrier-Based Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis and Moderna, etc.

By Company
  • Emergent BioSolutions
  • Sanofi
  • GlaxoSmithKline Biologicals
  • Merck
  • Pfizer
  • Novartis
  • Moderna
Segment by Type
  • Adjuvants
  • Delivery Systems
Segment by Application
  • Hospital
  • Clinic
  • Other
By Region
  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Nordic Countries
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East, Africa, and Latin America
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA
Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Nanocarrier-Based Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nanocarrier-Based Vaccine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.

Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nanocarrier-Based Vaccine revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW

1.1 Study Scope
1.2 Market Analysis by Type
  1.2.1 Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
  1.2.2 Adjuvants
  1.2.3 Delivery Systems
1.3 Market by Application
  1.3.1 Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Nanocarrier-Based Vaccine Market Perspective (2018-2029)
2.2 Global Nanocarrier-Based Vaccine Growth Trends by Region
  2.2.1 Nanocarrier-Based Vaccine Market Size by Region: 2018 VS 2022 VS 2029
  2.2.2 Nanocarrier-Based Vaccine Historic Market Size by Region (2018-2023)
  2.2.3 Nanocarrier-Based Vaccine Forecasted Market Size by Region (2024-2029)
2.3 Nanocarrier-Based Vaccine Market Dynamics
  2.3.1 Nanocarrier-Based Vaccine Industry Trends
  2.3.2 Nanocarrier-Based Vaccine Market Drivers
  2.3.3 Nanocarrier-Based Vaccine Market Challenges
  2.3.4 Nanocarrier-Based Vaccine Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Revenue Nanocarrier-Based Vaccine by Players
  3.1.1 Global Nanocarrier-Based Vaccine Revenue by Players (2018-2023)
  3.1.2 Global Nanocarrier-Based Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global Nanocarrier-Based Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Nanocarrier-Based Vaccine, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Nanocarrier-Based Vaccine Market Concentration Ratio
  3.4.1 Global Nanocarrier-Based Vaccine Market Concentration Ratio (CR5 and HHI)
  3.4.2 Global Top 10 and Top 5 Companies by Nanocarrier-Based Vaccine Revenue in 2022
3.5 Global Key Players of Nanocarrier-Based Vaccine Head office and Area Served
3.6 Global Key Players of Nanocarrier-Based Vaccine, Product and Application
3.7 Global Key Players of Nanocarrier-Based Vaccine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans

4 NANOCARRIER-BASED VACCINE BREAKDOWN DATA BY TYPE

4.1 Global Nanocarrier-Based Vaccine Historic Market Size by Type (2018-2023)
4.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029)

5 NANOCARRIER-BASED VACCINE BREAKDOWN DATA BY APPLICATION

5.1 Global Nanocarrier-Based Vaccine Historic Market Size by Application (2018-2023)
5.2 Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Nanocarrier-Based Vaccine Market Size (2018-2029)
6.2 North America Nanocarrier-Based Vaccine Market Size by Type
  6.2.1 North America Nanocarrier-Based Vaccine Market Size by Type (2018-2023)
  6.2.2 North America Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
  6.2.3 North America Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
6.3 North America Nanocarrier-Based Vaccine Market Size by Application
  6.3.1 North America Nanocarrier-Based Vaccine Market Size by Application (2018-2023)
  6.3.2 North America Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
  6.3.3 North America Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
6.4 North America Nanocarrier-Based Vaccine Market Size by Country
  6.4.1 North America Nanocarrier-Based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
  6.4.2 North America Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
  6.4.3 North America Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
  6.4.4 United States
  6.4.5 Canada

7 EUROPE

7.1 Europe Nanocarrier-Based Vaccine Market Size (2018-2029)
7.2 Europe Nanocarrier-Based Vaccine Market Size by Type
  7.2.1 Europe Nanocarrier-Based Vaccine Market Size by Type (2018-2023)
  7.2.2 Europe Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
  7.2.3 Europe Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
7.3 Europe Nanocarrier-Based Vaccine Market Size by Application
  7.3.1 Europe Nanocarrier-Based Vaccine Market Size by Application (2018-2023)
  7.3.2 Europe Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
  7.3.3 Europe Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
7.4 Europe Nanocarrier-Based Vaccine Market Size by Country
  7.4.1 Europe Nanocarrier-Based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
  7.4.2 Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
  7.4.3 Europe Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
  7.4.3 Germany
  7.4.4 France
  7.4.5 U.K.
  7.4.6 Italy
  7.4.7 Russia
  7.4.8 Nordic Countries

8 CHINA

8.1 China Nanocarrier-Based Vaccine Market Size (2018-2029)
8.2 China Nanocarrier-Based Vaccine Market Size by Type
  8.2.1 China Nanocarrier-Based Vaccine Market Size by Type (2018-2023)
  8.2.2 China Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
  8.2.3 China Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
8.3 China Nanocarrier-Based Vaccine Market Size by Application
  8.3.1 China Nanocarrier-Based Vaccine Market Size by Application (2018-2023)
  8.3.2 China Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
  8.3.3 China Nanocarrier-Based Vaccine Market Share by Application (2018-2029)

9 ASIA (EXCLUDING CHINA)

9.1 Asia Nanocarrier-Based Vaccine Market Size (2018-2029)
9.2 Asia Nanocarrier-Based Vaccine Market Size by Type
  9.2.1 Asia Nanocarrier-Based Vaccine Market Size by Type (2018-2023)
  9.2.2 Asia Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
  9.2.3 Asia Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
9.3 Asia Nanocarrier-Based Vaccine Market Size by Application
  9.3.1 Asia Nanocarrier-Based Vaccine Market Size by Application (2018-2023)
  9.3.2 Asia Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
  9.3.3 Asia Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
9.4 Asia Nanocarrier-Based Vaccine Market Size by Region
  9.4.1 Asia Nanocarrier-Based Vaccine Market Size by Region: 2018 VS 2022 VS 2029
  9.4.2 Asia Nanocarrier-Based Vaccine Market Size by Region (2018-2023)
  9.4.3 Asia Nanocarrier-Based Vaccine Market Size by Region (2024-2029)
  9.4.4 Japan
  9.4.5 South Korea
  9.4.6 China Taiwan
  9.4.7 Southeast Asia
  9.4.8 India
  9.4.9 Australia

10 MIDDLE EAST, AFRICA, AND LATIN AMERICA

10.1 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type
  10.2.1 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type (2018-2023)
  10.2.2 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type (2024-2029)
  10.2.3 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application
  10.3.1 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application (2018-2023)
  10.3.2 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application (2024-2029)
  10.3.3 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country
  10.4.1 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
  10.4.2 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2023)
  10.4.3 Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country (2024-2029)
  10.4.4 Brazil
  10.4.5 Mexico
  10.4.6 Turkey
  10.4.7 Saudi Arabia
  10.4.8 Israel
  10.4.9 GCC Countries

11 KEY PLAYERS PROFILES

11.1 Emergent BioSolutions
  11.1.1 Emergent BioSolutions Company Details
  11.1.2 Emergent BioSolutions Business Overview
  11.1.3 Emergent BioSolutions Nanocarrier-Based Vaccine Introduction
  11.1.4 Emergent BioSolutions Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
  11.1.5 Emergent BioSolutions Recent Developments
11.2 Sanofi
  11.2.1 Sanofi Company Details
  11.2.2 Sanofi Business Overview
  11.2.3 Sanofi Nanocarrier-Based Vaccine Introduction
  11.2.4 Sanofi Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
  11.2.5 Sanofi Recent Developments
11.3 GlaxoSmithKline Biologicals
  11.3.1 GlaxoSmithKline Biologicals Company Details
  11.3.2 GlaxoSmithKline Biologicals Business Overview
  11.3.3 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Introduction
  11.3.4 GlaxoSmithKline Biologicals Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
  11.3.5 GlaxoSmithKline Biologicals Recent Developments
11.4 Merck
  11.4.1 Merck Company Details
  11.4.2 Merck Business Overview
  11.4.3 Merck Nanocarrier-Based Vaccine Introduction
  11.4.4 Merck Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
  11.4.5 Merck Recent Developments
11.5 Pfizer
  11.5.1 Pfizer Company Details
  11.5.2 Pfizer Business Overview
  11.5.3 Pfizer Nanocarrier-Based Vaccine Introduction
  11.5.4 Pfizer Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
  11.5.5 Pfizer Recent Developments
11.6 Novartis
  11.6.1 Novartis Company Details
  11.6.2 Novartis Business Overview
  11.6.3 Novartis Nanocarrier-Based Vaccine Introduction
  11.6.4 Novartis Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
  11.6.5 Novartis Recent Developments
11.7 Moderna
  11.7.1 Moderna Company Details
  11.7.2 Moderna Business Overview
  11.7.3 Moderna Nanocarrier-Based Vaccine Introduction
  11.7.4 Moderna Revenue in Nanocarrier-Based Vaccine Business (2018-2023)
  11.7.5 Moderna Recent Developments

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology
  13.1.1 Methodology/Research Approach
  13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES

Table 1. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Adjuvants
Table 3. Key Players of Delivery Systems
Table 4. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Nanocarrier-Based Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Nanocarrier-Based Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Nanocarrier-Based Vaccine Market Share by Region (2018-2023)
Table 8. Global Nanocarrier-Based Vaccine Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Nanocarrier-Based Vaccine Market Share by Region (2024-2029)
Table 10. Nanocarrier-Based Vaccine Market Trends
Table 11. Nanocarrier-Based Vaccine Market Drivers
Table 12. Nanocarrier-Based Vaccine Market Challenges
Table 13. Nanocarrier-Based Vaccine Market Restraints
Table 14. Global Nanocarrier-Based Vaccine Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Nanocarrier-Based Vaccine Revenue Share by Players (2018-2023)
Table 16. Global Top Nanocarrier-Based Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
Table 17. Global Nanocarrier-Based Vaccine Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Nanocarrier-Based Vaccine Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Nanocarrier-Based Vaccine, Headquarters and Area Served
Table 20. Global Key Players of Nanocarrier-Based Vaccine, Product and Application
Table 21. Global Key Players of Nanocarrier-Based Vaccine, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Nanocarrier-Based Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2018-2023)
Table 25. Global Nanocarrier-Based Vaccine Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2024-2029)
Table 27. Global Nanocarrier-Based Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Nanocarrier-Based Vaccine Revenue Share by Application (2018-2023)
Table 29. Global Nanocarrier-Based Vaccine Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Nanocarrier-Based Vaccine Revenue Share by Application (2024-2029)
Table 31. North America Nanocarrier-Based Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Nanocarrier-Based Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Nanocarrier-Based Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Nanocarrier-Based Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Nanocarrier-Based Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Nanocarrier-Based Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Nanocarrier-Based Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Nanocarrier-Based Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Nanocarrier-Based Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Nanocarrier-Based Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Nanocarrier-Based Vaccine Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Nanocarrier-Based Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Nanocarrier-Based Vaccine Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size by Country (2024-2029) & (US$ Million)
Table 63. Emergent BioSolutions Company Details
Table 64. Emergent BioSolutions Business Overview
Table 65. Emergent BioSolutions Nanocarrier-Based Vaccine Product
Table 66. Emergent BioSolutions Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 67. Emergent BioSolutions Recent Developments
Table 68. Sanofi Company Details
Table 69. Sanofi Business Overview
Table 70. Sanofi Nanocarrier-Based Vaccine Product
Table 71. Sanofi Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 72. Sanofi Recent Developments
Table 73. GlaxoSmithKline Biologicals Company Details
Table 74. GlaxoSmithKline Biologicals Business Overview
Table 75. GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Product
Table 76. GlaxoSmithKline Biologicals Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 77. GlaxoSmithKline Biologicals Recent Developments
Table 78. Merck Company Details
Table 79. Merck Business Overview
Table 80. Merck Nanocarrier-Based Vaccine Product
Table 81. Merck Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 82. Merck Recent Developments
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Nanocarrier-Based Vaccine Product
Table 86. Pfizer Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 87. Pfizer Recent Developments
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Nanocarrier-Based Vaccine Product
Table 91. Novartis Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 92. Novartis Recent Developments
Table 93. Moderna Company Details
Table 94. Moderna Business Overview
Table 95. Moderna Nanocarrier-Based Vaccine Product
Table 96. Moderna Revenue in Nanocarrier-Based Vaccine Business (2018-2023) & (US$ Million)
Table 97. Moderna Recent Developments
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources

LIST OF FIGURES

Figure 1. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Nanocarrier-Based Vaccine Market Share by Type: 2022 VS 2029
Figure 3. Adjuvants Features
Figure 4. Delivery Systems Features
Figure 5. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Nanocarrier-Based Vaccine Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. Nanocarrier-Based Vaccine Report Years Considered
Figure 11. Global Nanocarrier-Based Vaccine Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Nanocarrier-Based Vaccine Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Nanocarrier-Based Vaccine Market Share by Region: 2022 VS 2029
Figure 14. Global Nanocarrier-Based Vaccine Market Share by Players in 2022
Figure 15. Global Top Nanocarrier-Based Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanocarrier-Based Vaccine as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Nanocarrier-Based Vaccine Revenue in 2022
Figure 17. North America Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 19. North America Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 20. North America Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 21. United States Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Nanocarrier-Based Vaccine Market Size YoY (2018-2029) & (US$ Million)
Figure 24. Europe Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 25. Europe Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 26. Europe Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 27. Germany Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. China Nanocarrier-Based Vaccine Market Size YoY (2018-2029) & (US$ Million)
Figure 34. China Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 35. China Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 36. Asia Nanocarrier-Based Vaccine Market Size YoY (2018-2029) & (US$ Million)
Figure 37. Asia Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 38. Asia Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 39. Asia Nanocarrier-Based Vaccine Market Share by Region (2018-2029)
Figure 40. Japan Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. South Korea Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. China Taiwan Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Southeast Asia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. India Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Australia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Size YoY (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Type (2018-2029)
Figure 48. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Application (2018-2029)
Figure 49. Middle East, Africa, and Latin America Nanocarrier-Based Vaccine Market Share by Country (2018-2029)
Figure 50. Brazil Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Mexico Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Turkey Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Israel Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. GCC Countries Nanocarrier-Based Vaccine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Emergent BioSolutions Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 57. Sanofi Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 58. GlaxoSmithKline Biologicals Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 59. Merck Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 60. Pfizer Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 61. Novartis Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 62. Moderna Revenue Growth Rate in Nanocarrier-Based Vaccine Business (2018-2023)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed


More Publications